
Apr 3, 2025, 09:13
Myeloma Paper of the Day, April 3rd, suggested by Robert Orlowski
Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day: Real-world evaluation of teclistamab for relapsed/refractory myeloma from IMWG finds ORR 67% (55% VGPR or better); 6-month PFS and OS 53% and 73%; patients with prior BCMA had lower ORR (58.3 vs 74.0%) and PFS (6-mo PFS 43% vs. 63%).”
Authors: Carlyn Rose Tan, Sireesha Asoori, Chiung-Yu Huang, Larissa Brunaldi, Rakesh Popat, Brian Durie, Saad Usmani, Thomas Martin, Yi Lin et al.
More posts featuring Robert Orlowski.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 3, 2025, 09:13
Apr 3, 2025, 08:47